Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Limb-Girdle Muscular Dystrophy (LGMD): Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This report provides a data ...

During the past decade, partnerships were the most frequent type of deal in North America and Asia-Pacific. Meanwhile, in Europe, mergers and licensing agreements contributed to an equal number of ...

Limb-girdle muscular dystrophies constitute a broad range of clinical and genetic entities. We have evaluated 38 autosomal recessive limb-girdle muscular dystrophy (LGMD2) families by linkage analysis ...

A spokesperson for the developer said a £4.7 million contract of works is starting this week, which will remedy the problems ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

One thing that sticks with me is how earnest the documentary feels. Steen was both a dear and considerate friend to the ...

The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

Full functional recovery has been achieved in an entire muscle using AAV vector-mediated gene therapy in a limb girdle muscular dystrophy hamster model, which has a mutation in the 1.2-kb gene for ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.